2|0|Public
5000|$|Ritipenem is a penem class {{antimicrobial}} agent. Ritipenem is {{manufactured by}} Tanabe Seiyaku in the ritipenem <b>acoxil</b> prodrug form, {{which can be}} taken orally [...] It is not FDA approved in the United States as of 2008.|$|E
40|$|A beta-lactamase-stable antibiotic, {{the oral}} penem FCE 22891 (ritipenem <b>acoxil),</b> was {{investigated}} {{for use in}} exacerbations of {{chronic obstructive pulmonary disease}} (COPD). Thirteen of the 15 COPD patients had a proven lower respiratory tract infection. Symptom scores and forced expiratory volumes in 1 s significantly improved during therapy with FCE 22891 in combination with bronchodilators and intravenous corticosteroids. Conversion of representative sputum to nonrepresentative sputum or eradication of the original pathogen in representative sputum was effected in 12 patients. Resistance to FCE 22891 was observed in three cases with Haemophilus influenzae. Gastrointestinal disturbances, of which one was severe, were experienced by eight patients. Although FCE 22891 has some beneficial effect in exacerbations of COPD, there are reservations about its use because of adverse effects and potential inefficacy in the treatment of infection with H. influenzae...|$|E

